Methylphenidate for children and adolescents with autism spectrum disorder
The studies: we included four cross‐over studies, with a total of 113 children aged 5 to 13 years, most of whom (83%) were boys. We included two studies with five‐year‐old children since we were unable to obtain the disaggregated data for those aged six years and above, and all other participants were in our target age range. All participants resided in the USA. The duration of treatment in the cross‐over phase was one week for each dose of methylphenidate. Studies used a range of outcome scales, rated by parents, teachers or both; clinicians; or programme staff. We report parent‐rated outcomes separately.
Methylphenidate for children and adolescents with autism spectrum disorder
Children with autistic spectrum disorder (ASD) frequently present with inattention, impulsivity and hyperactivity, which are the cardinal symptoms of attention…
www.ncbi.nlm.nih.gov
